Principal Investigator
Richard Preston
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20210048
Clinical Trial Summary
Protocol Number: CB8025-11942
A Phase 1, Open-Label, Pharmacokinetic Study of Seladelpar in Subjects with Mild, Moderate, or Severe Renal Impairment
Phase
Phase I
Funding Agency/Sponsor
Industry
Disease
Other